Keytruda is a brand (trade) name for pembrolizumab. It's given by intravenous infusion every 3 to 6 weeks. Almost never, the use of Keytruda results while in the immune system attacking healthier tissues which can cause severe side effects which include pneumonitis, colitis, or hepatitis. In a lot of people, the use of Keytruda has resulted in the